#USA #Upsher-Smith #Duchenne Muscular Dystrophy #Maple Grove #KYMBEE™

Upsher-Smith Expands KYMBEE™ Family with New Oral Suspension

In an exciting development for families affected by Duchenne muscular dystrophy (DMD), Upsher-Smith Laboratories, a well-known pharmaceutical company, has launched a new oral suspension of their product KYMBEE™ (deflazacort). This innovative formulation is designed for patients aged two years and older, providing them with a flexible and convenient treatment option that complements the existing tablet form.

What is Duchenne Muscular Dystrophy?

Duchenne muscular dystrophy is a rare genetic disorder characterized by progressive muscle weakness due to mutations in the gene responsible for dystrophin, a protein critical for normal muscle function. It predominantly affects boys, with a diagnosis typically occurring around the age of four. Though there is currently no cure, various treatments, including medications like deflazacort, are utilized to slow disease progression and improve the quality of life for patients.

About the KYMBEE™ Oral Suspension

The newly launched KYMBEE™ oral suspension offers a 22.75 mg/mL formulation that allows for easier administration, especially for children who may struggle with swallowing tablets. It is manufactured in the United States and leverages high-quality components sourced from Italy, aligning with Upsher-Smith's commitment to quality and efficacy.

This oral suspension is unique in that it is fully supported by the company's comprehensive Promise of Support® Program, an initiative designed to assist families throughout the entirety of their treatment journey.

The Promise of Support® Program

The Promise of Support® Program by Upsher-Smith is dedicated to making access to KYMBEE™ as seamless as possible. This initiative includes:

• - Expert support for benefits investigation and navigation of insurance coverage
• - Assistance with prior authorizations and appeals
• - Copay assistance for qualified patients with commercial insurance
• - Bridge supplies to ensure therapy continuity
• - 24/7 access to pharmacists for personalized assistance
• - Free home delivery options and reminders for medication refills

Importance of Treatment Options

Michelle Zachman, the Medical Affairs Director at Upsher-Smith, emphasized the importance of diverse treatment options for families managing deflazacort therapy. The addition of the oral suspension to the existing tablet formulation aims to cater to the varying needs of patients and their caregivers. “Our goal is to provide effective treatment options that are easy and accessible for everyone involved in managing DMD,” she stated.

Safety and Side Effects

As with any medication, patients and caregivers should be aware of the potential side effects associated with KYMBEE™. It can lead to changes in hormone function, increased risk of infections, and numerous other concerns that patients should discuss with their healthcare providers. The safety profile necessitates close monitoring by medical professionals during treatment.

How to Learn More

Families and healthcare providers interested in KYMBEE™ are encouraged to ask their doctors for more information. For more details, patients can visit the website designated for caregivers at https://mykymbee.com/caregiver or healthcare professionals at https://mykymbee.com/hcp. Upsher-Smith is also available for direct inquiries at 1-888-650-3789.

Conclusion

The introduction of the KYMBEE™ oral suspension signifies a promising step forward in the management of Duchenne muscular dystrophy, presenting a new, user-friendly option for families. Upsher-Smith's dedication to support and innovative treatment options demonstrates their ongoing commitment to improving the lives of those affected by this challenging condition. For more information on Upsher-Smith Laboratories, visit their official site at www.upsher-smith.com.

About Upsher-Smith Laboratories

Upsher-Smith Laboratories, LLC is a trusted name in the pharmaceutical industry, striving to improve patient outcomes through high-quality products and a strong commitment to service. As a member of Bora Pharmaceuticals, the company continues to innovate and expand its product offerings to meet the needs of patients worldwide.